A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

Key Inclusion Criteria:

* Be healthy, immunocompetent males or females ≥ 18 years of age
* Present with ≥ 2 and ≤ 30 external genital and/or perianal warts in ≥ 1 of the following anatomic areas:

  * In both sexes: medial thigh (except inguinal fold); supra-pubic, perineal, and perianal areas
  * In men: over the glans penis (excluding urethral meatus), penis shaft, scrotum, and foreskin
  * In women: vulva (excluding labia minora and mucosal surfaces)
* Have warts present for ≥ 4 weeks at the baseline visit
* Have warts that are ≤ 8 mm in diameter each

Key Exclusion Criteria:

* Have a wart within the allowed treatment area \> 8 mm in diameter or with an eroded or ulcerated surface, in the Investigator's opinion
* Have an unclear diagnosis of condyloma
* Have any wart types other than genital warts (e.g., common or plantar warts) that require treatment during the study period
* Have active genital herpes eruption, or had active genital herpes lesions within 4 weeks before enrollment
* Have a history of neoplasia or other HPV-associated malignancies within the last 5 years
* Are systemically immunosuppressed
* Are sexually active or may become sexually active and are unwilling to practice responsible birth control methods
* Are pregnant or breastfeeding